logo

Article

Biosimilars Versus Generics: Differences in the Regulatory Review Process

Conference|ASHP Midyear Clinical Meeting and Exhibition - American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition

Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

At the American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discussed the regulatory review process for biosimilars and how it differs from the generic review process.

Related Videos
AAN 2025: Paving the Way for Precision Medicine in Alzheimer, Neurodegenerative Diseases
AAN 2025: Paving the Way for Precision Medicine in Alzheimer, Neurodegenerative Diseases
ELCC 2025: Amivantamab Plus Lazertinib Effective in EGFR-Mutated NSCLC Versus Standard of Care
ELCC 2025: Amivantamab Plus Lazertinib Effective in EGFR-Mutated NSCLC Versus Standard of Care
Finerenone Shows Promise in Heart Failure and Kidney Disease Management
Finerenone Shows Promise in Heart Failure and Kidney Disease Management
Cardiovascular Risks of BTK Inhibitors: What Pharmacists Need to Know
Cardiovascular Risks of BTK Inhibitors: What Pharmacists Need to Know
Personalized Prevention: Identifying At-Risk Patients With Image-Based Screening
Personalized Prevention: Identifying At-Risk Patients With Image-Based Screening
APhA 2025: Empowering Pharmacy Leaders With Mindful Self-Care Strategies
APhA 2025: Empowering Pharmacy Leaders With Mindful Self-Care Strategies
Sotatercept Demonstrates Its Potential in the Phase 3 ZENITH Trial
Sotatercept Demonstrates Its Potential in the Phase 3 ZENITH Trial
FINEARTS-HF Analysis: How Liver Biomarkers Influence Heart Failure Risk
FINEARTS-HF Analysis: How Liver Biomarkers Influence Heart Failure Risk
Semaglutide and Cardiovascular Risk Reduction: What the Latest Data Tell Us
Semaglutide and Cardiovascular Risk Reduction: What the Latest Data Tell Us
New Data Highlights Abelacimab’s Safety Advantage in Atrial Fibrillation
New Data Highlights Abelacimab’s Safety Advantage in Atrial Fibrillation
Related Content
Platelets forming a blood clot, AI Generative
April 4th 2025

Fitusiran Maintains Long-Term Bleeding Control in Hemophilia A or B, With or Without Inhibitors

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Integrated Multi-Omic Data: Powering Precision Medicine
April 3rd 2025

Integrated Multi-Omic Data: Powering Precision Medicine

Christian Olsen
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
NCCN 2025: Advancing Breast Cancer Risk Assessment and Prevention Strategies
April 1st 2025

NCCN 2025: Advancing Breast Cancer Risk Assessment and Prevention Strategies

Luke Halpern, Assistant Editor
Intravenous Immunoglobulin Plus Rituximab Effective Alternative Option for Refractory Autoimmune Disease Treatment
April 1st 2025

Intravenous Immunoglobulin Plus Rituximab Effective Alternative Option for Refractory Autoimmune Disease Treatment

Luke Halpern, Assistant Editor